Global Schistosomiasis Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Schistosomiasis Treatment Market Size

• The global schistosomiasis treatment market size was valued at USD 73.50 million in 2025 and is expected to reach USD 97.68 million by 2033, at a CAGR of 3.62% during the forecast period
• The market growth is primarily driven by ongoing WHO-led elimination programs, mass drug administration (MDA) campaigns using praziquantel, and increasing government and NGO funding for neglected tropical diseases, which continue to support sustained treatment demand in endemic regions across Africa, the Middle East, and parts of South America
• Furthermore, rising focus on global public health initiatives, improved diagnostic screening in endemic areas, and stronger pharmaceutical supply chain participation for anti-parasitic drugs is reinforcing treatment accessibility. These converging factors are steadily supporting market expansion, despite the disease being concentrated in low-income regions with limited commercial drug pricing dynamics

Schistosomiasis Treatment Market Analysis

• Schistosomiasis treatment, primarily based on antiparasitic drug therapy such as praziquantel, is increasingly vital in global neglected tropical disease control programs in both endemic and at-risk regions due to its high efficacy, low cost, and widespread integration into WHO-recommended mass drug administration (MDA) initiatives and public health strategies
• The escalating demand for schistosomiasis treatment is primarily fueled by the widespread disease burden in tropical and subtropical regions, growing global elimination initiatives, increasing funding from international health organizations, and rising implementation of large-scale preventive chemotherapy programs across high-risk populations
• North America dominated the schistosomiasis treatment market with the largest revenue share of 42.6% in 2025, characterized by advanced healthcare infrastructure, strong disease surveillance systems, higher diagnostic awareness, and increasing identification of travel-related and imported cases, alongside growing research and public health attention toward neglected tropical diseases
• Asia-Pacific is expected to be the fastest growing region in the schistosomiasis treatment market during the forecast period due to improving healthcare access, expanding public health screening programs, rising government initiatives for parasitic disease control, and increasing disease awareness in endemic pockets across the region
• Praziquantel segment dominated the treatment segment in 2025 with the largest market share of 78.3%, driven by its WHO essential medicine status, proven broad-spectrum efficacy against Schistosoma species, low cost, and extensive procurement and distribution through government and global health programs

Report Scope and Schistosomiasis Treatment Market Segmentation

Schistosomiasis Treatment Market Trends

“Expansion of Mass Drug Administration and Integrated Disease Control Programs”

• A significant and expanding trend in the global schistosomiasis treatment market is the scaling up of WHO-led mass drug administration (MDA) and integrated neglected tropical disease control programs across endemic regions, driven by increasing global health funding and elimination targets
• For instance, in recent years, the World Health Organization has expanded preventive chemotherapy programs distributing praziquantel in high-burden African countries to reduce infection prevalence and transmission rates among at-risk populations
• The strengthening integration of schistosomiasis treatment with broader public health initiatives such as water, sanitation, and hygiene (WASH) programs is improving long-term disease prevention outcomes and reducing reinfection cycles in endemic communities
• The adoption of community-based treatment delivery models is enabling wider access to praziquantel therapy, particularly in remote rural areas where healthcare infrastructure remains limited, improving treatment coverage and compliance rates
• The increasing use of digital health tools for disease mapping and treatment monitoring is improving program efficiency and enabling better targeting of high-risk populations in endemic zones
• This trend toward coordinated global elimination strategies and large-scale preventive treatment campaigns is reshaping disease management approaches and increasing reliance on standardized antiparasitic drug distribution systems

Schistosomiasis Treatment Market Dynamics

Driver

“Rising Disease Burden and Expansion of Global Elimination Initiatives”

• The increasing prevalence of schistosomiasis in tropical and subtropical regions, coupled with expanding global elimination initiatives, is a major driver accelerating demand for effective antiparasitic treatment solutions worldwide
• For instance, in 2024, multiple endemic countries in sub-Saharan Africa intensified nationwide praziquantel distribution campaigns supported by international health organizations to reduce infection rates among school-aged children and vulnerable populations
• Growing awareness of the long-term health complications of untreated schistosomiasis, including organ damage and chronic morbidity, is encouraging governments to prioritize early treatment and preventive chemotherapy programs
• Furthermore, increasing financial and technical support from organizations such as WHO and the World Bank is strengthening national disease control programs and improving access to essential medicines in low-income regions
• The rising focus on eliminating neglected tropical diseases as a public health priority is significantly driving sustained demand for schistosomiasis treatment therapies globally
• The increasing incorporation of school-based deworming programs is further accelerating treatment coverage and improving early intervention outcomes in high-risk pediatric populations
• Rising collaboration between governments and pharmaceutical manufacturers for low-cost praziquantel supply is enhancing drug availability and supporting large-scale treatment initiatives in endemic regions

Restraint/Challenge

“Limited Healthcare Access and Dependence on Donor Funding Constraints”

• Limited healthcare infrastructure in endemic regions and heavy dependence on international donor funding remain significant challenges restricting consistent access to schistosomiasis treatment in high-burden countries
• For instance, in several sub-Saharan African regions, treatment coverage gaps persist due to logistical constraints in drug distribution and inadequate rural healthcare delivery systems
• Irregular funding cycles from global health donors can disrupt mass drug administration programs, leading to inconsistent treatment availability and reduced program effectiveness in endemic communities
• In addition, low awareness levels and underdiagnosis in remote areas hinder timely treatment initiation, allowing continued disease transmission and reinfection cycles
• Overcoming these challenges through strengthened healthcare systems, sustained funding commitments, and improved community-based delivery mechanisms will be critical for long-term disease control and market stability
• Weak diagnostic infrastructure in remote endemic regions further delays case identification, reducing the efficiency of treatment programs
• Geographic barriers and limited transportation networks in rural areas continue to restrict timely drug distribution and follow-up treatment coverage

Schistosomiasis Treatment Market Scope

The market is segmented on the basis of site, drugs, type, end-users, and distribution channel.

• By Site

On the basis of site, the schistosomiasis treatment market is segmented into intestinal and urogenital. The intestinal segment dominated the market with the largest revenue share in 2025, driven by the higher global prevalence of intestinal schistosomiasis caused mainly by Schistosoma mansoni and Schistosoma japonicum. This form is the primary target of large-scale mass drug administration (MDA) programs across sub-Saharan Africa and parts of Asia. School-aged children represent the highest-risk group, further increasing treatment volume. Strong WHO-supported preventive chemotherapy initiatives continue to prioritize intestinal infections. Easy diagnosis through stool-based screening methods also supports widespread treatment adoption.

The urogenital segment is expected to witness the fastest growth rate from 2026 to 2033, driven by increasing recognition of Schistosoma haematobium-related complications such as bladder damage and infertility risks. Expanding female genital schistosomiasis awareness programs are improving diagnosis rates in endemic regions. Integration of treatment with reproductive and maternal health services is also expanding access. Rising government screening initiatives in Africa are further boosting detection. Improved urine-based diagnostic tools are enabling earlier intervention.

• By Drugs

On the basis of drugs, the schistosomiasis treatment market is segmented into praziquantel, metrifonate, oxamniquine, and others. The praziquantel segment dominated the market with the largest revenue share of 78.3% in 2025, driven by its WHO-recommended first-line status and proven effectiveness against all major Schistosoma species. It is widely used in mass drug administration campaigns due to its single-dose convenience and low cost. Global donation programs and government procurement ensure strong availability in endemic regions. Its inclusion in essential medicine lists further strengthens dominance. High treatment coverage across Africa reinforces its market leadership.

The others segment is expected to witness the fastest growth rate from 2026 to 2033, driven by ongoing research into alternative therapies and combination drug approaches. Concerns about potential reduced drug sensitivity are encouraging diversification beyond praziquantel. Development of pediatric formulations is also gaining traction. Pharmaceutical investments in novel antiparasitic compounds are increasing. Efforts to improve compliance and reduce reinfection rates are further supporting innovation.

• By Type

On the basis of type, the schistosomiasis treatment market is segmented into Schistosoma mansoni, Schistosoma japonicum, Schistosoma mekongi, Schistosoma guineensis, Schistosoma haematobium, and others. The Schistosoma mansoni segment dominated the market with the largest revenue share in 2025, driven by its widespread prevalence across sub-Saharan Africa and parts of South America. It is the leading cause of intestinal schistosomiasis, contributing significantly to global disease burden. Large-scale WHO elimination programs prioritize control of this species. High infection rates among rural populations increase treatment demand. Extensive epidemiological surveillance supports continued dominance of this segment.

The Schistosoma haematobium segment is expected to witness the fastest growth rate from 2026 to 2033, driven by increasing focus on urogenital complications and female genital schistosomiasis. Expanding awareness of long-term reproductive health impacts is improving diagnosis rates. Strengthened screening programs in African countries are identifying more cases. Integration with maternal health initiatives is expanding treatment access. Improved diagnostic tools are enabling earlier and more accurate detection.

• By End-Users

On the basis of end-users, the schistosomiasis treatment market is segmented into hospitals, homecare, specialty clinics, and others. The hospitals segment dominated the market with the largest revenue share in 2025, driven by centralized distribution of praziquantel through government and NGO-supported mass treatment programs. Hospitals serve as key hubs for diagnosis, drug administration, and monitoring of severe or complicated cases. Strong infrastructure support in endemic regions ensures high patient reach. Collaboration between governments and international health agencies strengthens hospital-based delivery. Bulk procurement systems further reinforce this segment’s dominance.

The homecare segment is expected to witness the fastest growth rate from 2026 to 2033, driven by increasing adoption of community-based treatment delivery models. Mass drug administration campaigns are increasingly conducted at household and school levels. Oral praziquantel therapy enables easy non-clinical administration. Rising healthcare accessibility in rural areas supports decentralized treatment. Growing awareness and public health outreach programs are further accelerating adoption.

• By Distribution Channel

On the basis of distribution channel, the schistosomiasis treatment market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market with the largest revenue share in 2025, driven by large-scale procurement for government-led mass drug administration programs. Hospital pharmacies act as primary distribution points for praziquantel in endemic regions. Strong institutional supply chains ensure consistent availability during public health campaigns. Integration with national health programs supports efficient drug allocation. Bulk purchasing by governments reinforces segment dominance.

The online pharmacy segment is expected to witness the fastest growth rate from 2026 to 2033, driven by increasing digital healthcare adoption and improved access to medicines in urban and semi-urban areas. Expansion of telemedicine services is supporting remote prescriptions and drug delivery. Growing awareness of parasitic diseases in non-endemic regions is increasing online demand. Convenience and faster accessibility are key growth drivers. Rising e-pharmacy platforms are further accelerating segment expansion.

Schistosomiasis Treatment Market Regional Analysis

• North America dominated the schistosomiasis treatment market with the largest revenue share of 42.6% in 2025, characterized by advanced healthcare infrastructure, strong disease surveillance systems, higher diagnostic awareness, and increasing identification of travel-related and imported cases, alongside growing research and public health attention toward neglected tropical diseases
• Healthcare providers in the region actively emphasize early diagnosis and treatment of schistosomiasis cases among travelers and immigrant populations returning from endemic areas
• The dominance is further supported by advanced healthcare infrastructure, strong research initiatives in neglected tropical diseases, and well-established access to antiparasitic therapies, ensuring effective disease management and reporting systems

U.S. Schistosomiasis Treatment Market Insight

The U.S. schistosomiasis treatment market captured the largest revenue share of 81% within North America in 2025, driven by high international travel rates and increased screening of imported parasitic infections. Healthcare professionals are increasingly focused on early diagnosis and treatment of travelers returning from endemic regions such as sub-Saharan Africa and Southeast Asia. The country’s advanced healthcare infrastructure, strong infectious disease surveillance systems, and availability of praziquantel support effective treatment outcomes. Furthermore, growing research activities in tropical and neglected diseases continue to strengthen market development.

Europe Schistosomiasis Treatment Market Insight

The Europe schistosomiasis treatment market is projected to expand at a moderate CAGR throughout the forecast period, primarily driven by increasing awareness of imported parasitic infections and strengthened public health surveillance systems. Rising international travel and migration from endemic regions are contributing to higher diagnosis rates across European countries. Government-supported healthcare systems and strong infectious disease monitoring frameworks are improving treatment accessibility. Furthermore, ongoing research initiatives focused on neglected tropical diseases are supporting steady market growth across the region.

U.K. Schistosomiasis Treatment Market Insight

The U.K. schistosomiasis treatment market is anticipated to grow at a steady CAGR during the forecast period, driven by increasing awareness of travel-acquired infections and strong healthcare screening practices. Rising international travel to and from endemic regions is contributing to higher detection of imported cases. The National Health Service (NHS) provides structured diagnostic and treatment pathways, supporting effective disease management. In addition, growing focus on tropical disease surveillance is further supporting market expansion in the country.

Germany Schistosomiasis Treatment Market Insight

The Germany schistosomiasis treatment market is expected to expand at a considerable CAGR during the forecast period, fueled by rising awareness of rare and imported parasitic diseases and strong diagnostic infrastructure. Germany’s advanced laboratory and hospital network supports early detection and treatment of schistosomiasis cases. Increasing focus on infectious disease research and global health preparedness is also contributing to market growth. Moreover, well-established healthcare coverage ensures timely access to antiparasitic therapies for diagnosed patients.

Asia-Pacific Schistosomiasis Treatment Market Insight

The Asia-Pacific schistosomiasis treatment market is poised to grow at the fastest CAGR during the forecast period, driven by high endemic disease burden, expanding public health programs, and increasing government focus on parasitic disease elimination. Countries such as China, Indonesia, and the Philippines are actively implementing mass drug administration and screening initiatives. Rising investments in healthcare infrastructure and improved access to diagnostic tools are further accelerating treatment adoption. In addition, growing awareness and international health support are enhancing disease control efforts across the region.

Japan Schistosomiasis Treatment Market Insight

The Japan schistosomiasis treatment market is gaining steady attention due to strong healthcare infrastructure and high awareness of infectious disease prevention, despite low endemic transmission. Most cases are travel-related, leading to efficient diagnosis and treatment through advanced hospital systems. Japan’s strong research ecosystem in parasitology and tropical medicine also supports market activity. Furthermore, integration of modern diagnostic technologies enhances early detection and treatment outcomes.

India Schistosomiasis Treatment Market Insight

The India schistosomiasis treatment market accounted for a growing share in Asia Pacific in 2025, attributed to improving healthcare infrastructure, expanding disease awareness, and increasing public health initiatives targeting parasitic infections. Although not highly endemic compared to African regions, imported and localized cases are being increasingly identified through better surveillance systems. Government focus on strengthening infectious disease control and expanding access to essential medicines is supporting market growth. In addition, rising participation in global elimination programs is further enhancing treatment availability and awareness.

Schistosomiasis Treatment Market Share

The Schistosomiasis Treatment industry is primarily led by well-established companies, including:

• Merck & Co., Inc. (U.S.)
• Bayer AG (Germany)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• GSK plc (U.K.)
• Abbott (U.S.)
• AstraZeneca plc (U.K.)
• Cipla Ltd. (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Dr. Reddy’s Laboratories Ltd. (India)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Mylan N.V. (U.S.)
• Astellas Pharma Inc. (Japan)
• Eisai Co., Ltd. (Japan)
• Takeda Pharmaceutical Company Limited (Japan)
• Zydus Lifesciences Ltd. (India)
• Boehringer Ingelheim GmbH (Germany)
• EIPICO (Egypt)

What are the Recent Developments in Global Schistosomiasis Treatment Market?

• In March 2025, the Pediatric Praziquantel Consortium announced the first treatment administration of a new pediatric schistosomiasis therapy (arpraziquantel) in Uganda, marking a major milestone in addressing preschool-aged children previously excluded from treatment programs. The therapy is designed as a child-friendly, dispersible tablet and supports WHO elimination goals. The rollout strengthens access to age-appropriate treatment in high-burden regions
• In March 2025, WHO-supported partners in Senegal initiated preparations for national rollout of pediatric praziquantel (arpraziquantel) under structured implementation research programs. The initiative focuses on integrating treatment into mass drug administration campaigns targeting young children. It also aims to strengthen healthcare delivery systems for equitable access. The program is part of broader global elimination efforts
• In May 2024, the World Health Organization added a new pediatric schistosomiasis treatment formulation (arpraziquantel) to its List of Prequalified Medicines, improving global procurement and distribution pathways. This inclusion ensures higher quality assurance for international health agencies and governments. It supports large-scale adoption in endemic countries. The listing is a key step toward wider global rollout
• In February 2024, WHO and global partners announced efforts to prepare country readiness for pediatric schistosomiasis treatment access across endemic regions, focusing on regulatory approval and delivery systems. The initiative addresses long-standing treatment gaps in preschool-aged children. It emphasizes coordinated implementation strategies across African nations. This development strengthens global elimination planning
• In January 2024, WHO-backed programs supported the introduction of pediatric arpraziquantel pilot programs in Tanzania, focusing on evaluating delivery models for schistosomiasis treatment. The initiative is designed to optimize mass drug administration efficiency in children under five. It also assesses barriers to large-scale implementation. The project supports future national-scale rollout strategies

SKU-54131